The ASCO/ASTRO/SSO guidelines recommend offering CRRM for women with breast cancer carrying a BRCA1 or BRCA2 P/LP variant and who have been treated or are being treated with unilateral mastectomy [151]. This evidence concerns the gene BRCA2 and breast carcinoma.